![](/img/cover-not-exists.png)
Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer
C Dittrich, B Coudert, L Paz-Ares, F Caponigro, M Salzberg, T Gamucci, X Paoletti, C Hermans, D Lacombe, P FumoleauVolume:
39
Year:
2003
Language:
english
DOI:
10.1016/s0959-8049(02)00559-2
File:
PDF, 108 KB
english, 2003